KALA BIO, INC. Cost of Revenue
KALA BIO, INC. (KALA) reported Cost of Revenue of $241.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2019-05-09
- KALA BIO, INC. cost of goods and services sold for the quarter ending 2019-03-31 was $241.00K.
| Period end | Cost of Goods and Services Sold 3 month |
|---|---|
| 2019-03-31 | $241.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |